Higher doses of LSD can alleviate the symptoms of moderate to severe anxiety disorder

Publicly released:
International
CC-0. https://www.needpix.com/photo/download/307931/psychedelic-colours-vibrant-rainbow-retro-design-pattern-illusion-disturbing
CC-0. https://www.needpix.com/photo/download/307931/psychedelic-colours-vibrant-rainbow-retro-design-pattern-illusion-disturbing

It may sound counterintuitive, but US scientists say taking the psychedelic drug LSD (lysergic acid diethylamide) appears to help alleviate the symptoms of moderate to severe generalised anxiety disorder (GAD), with higher doses more effective than lower doses. The team ran a 'gold standard' clinical trial including 198 people with GAD, who were given one of four different doses of a drug called MM120 (lysergide D-tartrate) - a pharmaceutical form of LSD that can be taken orally - or an inactive treatment for comparison. Their anxiety symptoms were assessed before and after the single-dose treatment in a controlled environment. Analysing the results, the researchers found no difference in symptoms among patients given the lowest doses of 25 or 50 micrograms, but improvements were seen in those given 100 or 200 micrograms. The most common side effects were, unsurprisingly, visual hallucinations, followed by nausea and headache, but nobody appears to have suffered a 'bad trip'. The scientists say their results support further investigation of higher-dose LSD for the treatment of GAD.

Media release

From: JAMA

Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder

In participants with moderate to severe generalized anxiety disorder, a single dose of MM120 (lysergide D-tartrate) produced a dose-dependent reduction in anxiety. Lysergide, or lysergic acid diethylamide (LSD), is a semisynthetic psychedelic drug. An oral pharmaceutical formulation of LSD is MM120. These results support the dose-dependent efficacy of MM120 and inform the dose selection for phase 3 pivotal trials.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page
Editorial / Opinion JAMA, Web page
Journal/
conference:
JAMA
Research:Paper
Organisation/s: Mind Medicine (MindMed) Inc., USA
Funder: The study was funded by Mind Medicine (MindMed) Inc. The study sponsor also supplied the drug product.
Media Contact/s
Contact details are only visible to registered journalists.